retatrutide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
The reign of the young Władysław III (1434–44), who succeeded his father Władysław II Jagiełło and ruled as king of Poland and Hungary, was cut short by his death at the Battle of Varna, during a crusade against the Ottoman Empire. This disaster led to an interregnum of three years that ended with the accession of Władysław's brother Casimir IV Jagiellon in 1447. Critical developments of the Jagiellonian period were concentrated during Casimir IV's long reign, which lasted until 1492. In 1454, Royal Prussia was incorporated by Poland and the Thirteen Years' War of 1454–66 with the Teutonic state ensued. In 1466, the milestone Peace of Thorn was concluded. This treaty divided Prussia to create East Prussia, the future Duchy of Prussia, a separate entity that functioned as a fief of Poland under the administration of the Teutonic Knights. Poland also confronted the Ottoman Empire and the Crimean Tatars in the south, and in the east helped Lithuania fight the Grand Duchy of Moscow. The country was developing as a feudal state, with a predominantly agricultural economy and an increasingly dominant landed nobility. Kraków, the royal capital, was turning into a major academic and cultural center, and in 1473 the first printing press began operating there. With the growing importance of szlachta (middle and lower nobility), the king's council evolved to become by 1493 a bicameral General Sejm (parliament) that no longer represented exclusively top dignitaries of the realm.
Soft balancing was developed in the 2000s to account for the contemporary anomaly of the unipolar unbalanced world. Thomas Mowle and David Sacko describe "soft balancing" as "balancing that does not balance at all." These theoretical efforts are counter-productive, since Realism and unipolarity are compatible and structural realism should rather develop a set of hypotheses for a unipolar world: "Scholars do not need to desperately search for signs of balancing, they do not need to soften balancing beyond recognition, and they do not need to stand to watch for the first glimmering of a new multipolar dawn." Campbell Craig explained the development of soft balancing theory on the Thomas Kuhn's three-stage model how scholarly communities respond to anomalies that seem clearly to defy their core theoretical predictions:
The goal of a vaccine is to stimulate the adaptive immune system to create antibodies that precisely target that particular pathogen. The markers on the pathogen that the antibodies target are called antigens. Traditional vaccines stimulate an antibody response by injecting either antigens, an attenuated (weakened) virus, an inactivated (dead) virus, or a recombinant antigen-encoding viral vector (harmless carrier virus with an antigen transgene) into the body. These antigens and viruses are prepared and grown outside the body. In contrast, mRNA vaccines introduce a short-lived synthetically created fragment of the RNA sequence of a virus into the individual being vaccinated. These mRNA fragments are taken up by dendritic cells through phagocytosis. The dendritic cells use their internal machinery (ribosomes) to read the mRNA and produce the viral antigens that the mRNA encodes. The body degrades the mRNA fragments within a few days of introduction. Although non-immune cells can potentially also absorb vaccine mRNA, produce antigens, and display the antigens on their surfaces, dendritic cells absorb the mRNA globules much more readily. The mRNA fragments are translated in the cytoplasm and do not affect the body's genomic DNA, located separately in the cell nucleus. Once the viral antigens are produced by the host cell, the normal adaptive immune system processes are followed. Antigens are broken down by proteasomes. Class I and class II MHC molecules then attach to the antigen and transport it to the cellular membrane, "activating" the dendritic cell.
==== High resolution melting analysis (HRM) ==== A further method to differentiate converted from unconverted bisulfite-treated DNA is using high-resolution melting analysis (HRM), a quantitative PCR-based technique initially designed to distinguish SNPs. The PCR amplicons are analyzed directly by temperature ramping and resulting liberation of an intercalating fluorescent dye during melting. The degree of methylation, as represented by the C-to-T content in the amplicon, determines the rapidity of melting and consequent release of the dye. This method allows direct quantitation in a single-tube assay, but assesses methylation in the amplified region as a whole rather than at specific CpG sites.
is the Avogadro constant Assuming concentration gradient is constant for all newly applied topical drugs and the temperature is constant (normal body temperature: 37 °C), the viscosity and radius of the drug determine the flux of diffusion. The higher the viscosity or the larger the radius of the drug is, the lower the diffusion flux of the drug is.
Sources: en.wikipedia.org
The depth of a stage 4 pressure ulcer varies by anatomical location. The bridge of the nose, ear, occiput and malleolus do not have (adipose) subcutaneous tissue and these ulcers can be shallow. Stage 4 ulcers can extend into muscle and/or supporting structures (e.g., fascia, tendon or joint capsule) making osteomyelitis likely to occur. Exposed bone/tendon is visible or directly palpable. In 2012, the National Pressure Injury Advisory Panel stated that pressure ulcers with exposed cartilage are also classified as a stage 4. Unstageable: Full thickness tissue loss in which actual depth of the ulcer is completely obscured by slough (yellow, tan, gray, green or brown) and/or eschar (tan, brown or black) in the wound bed. Until enough slough and/or eschar is removed to expose the base of the wound, the true depth, and therefore stage, cannot be determined. Stable (dry, adherent, intact without erythema or fluctuance) eschar on the heels is normally protective and should not be removed. Deep tissue pressure injury (formerly suspected deep tissue injury): Intact or non-intact skin with localized area of persistent non-blanchable deep red, maroon, purple discoloration or epidermal separation revealing a dark wound bed or blood filled blister. Pain and temperature change often precede skin color changes. Discoloration may appear differently in darkly pigmented skin. This injury results from intense and/or prolonged pressure and shear forces at the bone-muscle interface. The wound may evolve rapidly to reveal the actual extent of tissue injury, or may resolve without tissue loss.
SASP induces an unfolded protein response in the endoplasmic reticulum because of an accumulation of unfolded proteins, resulting in proteotoxic impairment of cell function. SASP cytokines can result in an inflamed stem cell niche, leading to stem cell exhaustion and impaired stem cell function. The pro-inflammatory environment generated by SASP factors accelerates the breakdown of extracellular matrix thereby worsening intervertebral disc degeneration (IVDD). AMPK/p53 senescence produces a completely different SASP than IL-1 (p16INK4a) senescence, which is primarily responsible for IVDD. In IVDD, SASP is secreted by nucleus pulposus and annulus fibrosus cells, resulting in extracellular matrix degradation and extracellular inflammation. Senomorphics, but not senolytics have been found to alleviate symptoms without eliminating senescent cells. SASP can either promote or inhibit cancer, depending on the SASP composition, notably including p53 status. Despite the fact that cellular senescence likely evolved as a means of protecting against cancer early in life, SASP promotes the development of late-life cancers. Cancer invasiveness is promoted primarily through the actions of the SASP factors metalloproteinase, chemokine, interleukin 6 (IL-6), and interleukin 8 (IL-8). In fact, SASP from senescent cells is associated with many aging-associated diseases, including not only cancer, but atherosclerosis and osteoarthritis. For this reason, senolytic therapy has been proposed as a generalized treatment for these and many other diseases.
In 1389 the Bishop of Troyes sent a memorial to Antipope Clement VII, declaring that the cloth had been "artificially painted in an ingenious way" and that "it was also proved by the artist who had painted it that it was made by human work, not miraculously produced". In 1390 Clement VII consequently issued four papal bulls, with which he allowed the exposition, but ordered to "say aloud, to put an end to all fraud, that the aforementioned representation is not the true Shroud of Our Lord Jesus Christ, but a painting or panel made to represent or imitate the Shroud". However, in 1506 Pope Julius II reversed this position and permitted the faithful who believe the Shroud to be authentic to venerate it as such, authorizing the public veneration of it with its own mass and office. The Vatican newspaper L'Osservatore Romano covered the story of Secondo Pia's photograph of 28 May 1898 in its edition of 15 June 1898, but it did so with no comment and thereafter Church officials generally refrained from officially commenting on the photograph for almost half a century. The first official modern association between the Shroud and the official Catholic Church dates from 1940, when Sister Maria Pierina De Micheli approached the curia of Milan requesting authorization to produce a devotional medal based on the image of Jesus's face from the Shroud. This "Holy Face Medal" was approved by Pope Pius XII and it was initially used as a means of protection during the Second World War.
==== Nazca plate ==== Juan Fernández hotspot (16) 33°54′S 81°48′W, w= 1 az= 084° ±3° rate= 80 ±20 mm/yr San Felix hotspot (36) 26°24′S 80°06′W, w= 0.3 az= 083° ±8° Easter hotspot (7) 26°24′S 106°30′W, w= 1 az= 087° ±3° rate= 95 ±5 mm/yr Galápagos hotspot (10) 0°24′S 91°36′W Nazca Plate, w= 1 az= 096° ±5° rate= 55 ±8 mm/yr Cocos Plate, w= 0.5 az= 045° ±6° Possibly related to the Caribbean large igneous province (main events: 95–88 Ma).
== Medicine == Muscle contraction, the physiological condition of a muscle which generates tension (traction) at its origin and insertion Uterine contraction, contraction of the uterus, such as during childbirth Contractility, the intrinsic ability of the heart/myocardium to contract Wound contraction, a stage in wound healing
Sources: en.wikipedia.org
The ionizing radiation emitted by radium bromide excites nitrogen molecules in the air, making it glow. The alpha particles emitted by radium quickly gain two electrons to become neutral helium, which builds up inside and weakens radium bromide crystals. This effect sometimes causes the crystals to break or even explode. Radium nitrate (Ra(NO3)2) is a white compound that can be made by dissolving radium carbonate in nitric acid. As the concentration of nitric acid increases, the solubility of radium nitrate decreases, an important property for the chemical purification of radium. Radium forms much the same insoluble salts as its lighter congener barium: it forms the insoluble sulfate (RaSO4, the most insoluble known sulfate), chromate (RaCrO4), carbonate (RaCO3), iodate (Ra(IO3)2), tetrafluoroberyllate (RaBeF4), and nitrate (Ra(NO3)2). With the exception of the carbonate, all of these are less soluble in water than the corresponding barium salts, but they are all isostructural to their barium counterparts. Additionally, radium phosphate, oxalate, and sulfite are probably also insoluble, as they coprecipitate with the corresponding insoluble barium salts. The great insolubility of radium sulfate (at 20 °C, only 2.1 mg will dissolve in 1 kg of water) means that it is one of the less biologically dangerous radium compounds. The large ionic radius of Ra2+ (148 pm) results in weak ability to form coordination complexes and poor extraction of radium from aqueous solutions when not at high pH.
== Function == The protein encoded by this gene is an enzyme that belongs to the subtilisin-like proprotein convertase family. The members of this family are proprotein convertases that process latent precursor proteins into their biologically active products. This encoded protein is a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at their paired basic amino acid processing sites. Some of its substrates are: proparathyroid hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta-secretase, membrane type-1 matrix metalloproteinase, beta subunit of pro-nerve growth factor and von Willebrand factor. A furin-like pro-protein convertase has been implicated in the processing of RGMc (also called hemojuvelin), a gene involved in a severe iron-overload disorder called juvenile hemochromatosis. Both the Ganz and Rotwein groups demonstrated that furin-like proprotein convertases (PPC) are responsible for conversion of 50 kDa HJV to a 40 kDa protein with a truncated COOH-terminus, at a conserved polybasic RNRR site. This suggests a potential mechanism to generate the soluble forms of HJV/hemojuvelin (s-hemojuvelin) found in the blood of rodents and humans. The furin substrates and the locations of furin cleavage sites in protein sequences can be predicted by two bioinformatics methods: ProP and PiTou.
== Synthetic biology applications == In addition to its use as a naturally occurring probiotic, S. boulardii has attracted increasing interest as a chassis organism for synthetic biology and engineered microbial therapeutics. Its ability to survive gastrointestinal conditions, transiently persist in the gut, and its established safety record have motivated efforts to genetically modify S. boulardii for the localized delivery of therapeutic molecules. Engineered strains have been reported to express heterologous proteins such as the anti-inflammatory cytokine interleukin-10 (IL-10), with the aim of reducing intestinal inflammation, as well as peptide hormones including exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist investigated for metabolic and endocrine applications. Other engineered variants have been designed to secrete antimicrobial peptides, toxin-neutralizing enzymes, or immunomodulatory metabolites, or to modulate short-chain fatty acid production. Collectively, these approaches position S. boulardii as a promising platform for next-generation live biotherapeutic products (also called advanced microbiome therapeutics), leveraging synthetic biology to extend its therapeutic potential beyond that of conventional probiotics.
Body fat cells have regional responses to the overfeeding that was studied in adult subjects. In the upper body, an increase of adipocyte size correlated with upper-body fat gain; however, the number of fat cells was not significantly changed. In contrast to the upper body fat cell response, the number of lower-body adipocytes did significantly increase during the course of experiment. Notably, there was no change in the size of the lower-body adipocytes. Approximately 10% of fat cells are renewed annually at all adult ages and levels of body mass index without a significant increase in the overall number of adipocytes in adulthood.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.